Details of Disease

General Information of Disease (ID: DIS7DYEW)

Disease Name	Acute coronary syndrome
Synonyms	coronary syndrome, acute; coronary syndromes, acute; acute coronary syndromes; syndrome, acute coronary; syndromes, acute coronary; acute coronary syndrome
Disease Class	BA41-BA43: Myocardial infarction
Definition	Signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to myocardial infarction.
Disease Hierarchy	DIS6SVEE: Syndromic disease DISBV50J: Acute disease DIS7BEFE: Acute cardiac ischemic events DIS7DYEW: Acute coronary syndrome
ICD Code	ICD-11 ICD-11: BA41 ICD-9 ICD-9: 411.1 Expand ICD-9 411.1
Disease Identifiers	MONDO ID MONDO_0005542 MESH ID D054058 UMLS CUI C0948089 MedGen ID 215295 HPO ID HP:0033678 SNOMED CT ID 394659003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 15 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anistreplase	DM6Q4B0	Approved	NA	[1]
Aspirin	DM672AH	Approved	Small molecular drug	[2]
Atorvastatin	DMF28YC	Approved	Small molecular drug	[3]
Brilinta	DMBR01X	Approved	Small molecular drug	[4]
Citalopram	DM2G9AE	Approved	Small molecular drug	[5]
Clopidogrel	DMOL54H	Approved	Small molecular drug	[6]
Eptifibatide	DMQXTJS	Approved	Small molecular drug	[7]
M-enoxaparin	DM1MSGC	Approved	NA	[8]
Metoprolol	DMOJ0V6	Approved	Small molecular drug	[9]
Prasugrel	DM7MT6E	Approved	Small molecular drug	[10]
Ranolazine	DM0C9IL	Approved	Small molecular drug	[11]
Salicyclic acid	DM2F8XZ	Approved	Small molecular drug	[12]
Ticlopidine	DMO946V	Approved	Small molecular drug	[13]
Tirofiban	DMQG17S	Approved	Small molecular drug	[14]
Trapidil	DMY67U8	Phase 4	Small molecular drug	[15]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 Drug(s)

This Disease is Treated as An Indication in 11 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dalcetrapib	DMKNCVM	Phase 3	Small molecular drug	[16]
Losmapimod	DMIL37Z	Phase 3	Small molecular drug	[17]
REG1	DMRZHKL	Phase 3	NA	[18]
CER-001	DMWUQI9	Phase 2	NA	[19]
E5555	DMQERC6	Phase 2	Small molecular drug	[20]
M118	DML0I2Z	Phase 2	Small molecular drug	[21]
MEDI6012	DMU4CS8	Phase 2	NA	[22]
RO-4905417	DMV319J	Phase 2	Antibody	[23]
VT-111a	DMY9ZGN	Phase 2	NA	[24]
MDCO-216	DMAQ24G	Phase 1	NA	[25]
PF-06282999	DMU5761	Phase 1	NA	[26]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 Drug(s)

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Darexaban maleate	DMC40SD	Discontinued in Phase 3	Small molecular drug	[27]
RG1512	DM8L6KO	Discontinued in Phase 2	NA	[28]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LA-8045	DMWIE8B	Investigative	NA	[29]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 75 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACTG1	TTGAZF9	Limited	Biomarker	[31]
CDH6	TT9QHUK	Limited	Biomarker	[32]
GAPDH	TTUGSWA	Limited	Biomarker	[31]
GREM1	TTOUZN5	Limited	Biomarker	[33]
GSN	TTUH7OM	Limited	Biomarker	[31]
GSTP1	TT40K12	Limited	Biomarker	[31]
HSPA8	TTMQL3K	Limited	Biomarker	[31]
JUP	TTREN0G	Limited	Biomarker	[34]
SERPINC1	TT4QPUL	Limited	Therapeutic	[35]
TLR4	TTISGCA	Limited	Altered Expression	[36]
TNFRSF9	TTPW9LJ	Limited	Biomarker	[37]
TUBB1	TT63KYR	Limited	Biomarker	[31]
P2RY1	TTA93TL	moderate	Biomarker	[38]
PLA2G2A	TTO8QRU	moderate	Genetic Variation	[39]
PTGER2	TT1ZAVI	moderate	Genetic Variation	[40]
TNFSF4	TTBW580	moderate	Genetic Variation	[41]
ADAMTS4	TTYG6BU	Strong	Altered Expression	[42]
ADRB1	TTR6W5O	Strong	Genetic Variation	[43]
ADRB2	TTG8ZWP	Strong	Genetic Variation	[44]
ALOX5AP	TTDMBF5	Strong	Genetic Variation	[45]
APCS	TTB7VAT	Strong	Biomarker	[46]
APOA1	TT5S8DR	Strong	Biomarker	[47]
APOE	TTKS9CB	Strong	Genetic Variation	[48]
BSG	TT5UJWD	Strong	Biomarker	[49]
CAD	TT2YT1K	Strong	Biomarker	[50]
CARM1	TTIZQFJ	Strong	Biomarker	[51]
CCN1	TTPK79J	Strong	Biomarker	[52]
CD40	TT1ERKL	Strong	Biomarker	[53]
CD40LG	TTIJP3Q	Strong	Biomarker	[53]
CPB2	TTP18AY	Strong	Biomarker	[54]
CRP	TTWRN6M	Strong	Altered Expression	[55]
CUBN	TT9YLCR	Strong	Genetic Variation	[56]
CX3CR1	TT2T98G	Strong	Genetic Variation	[57]
CYP2C19	TTZ58XG	Strong	Biomarker	[58]
EPHX2	TT7WVHI	Strong	Genetic Variation	[59]
F10	TTCIHJA	Strong	Biomarker	[60]
F12	TTRJSMV	Strong	Altered Expression	[61]
F2R	TTL935N	Strong	Biomarker	[62]
F3	TT38MDJ	Strong	Altered Expression	[63]
F7	TTF0EGX	Strong	Biomarker	[64]
FASN	TT7AOUD	Strong	Biomarker	[65]
FHIT	TTMS54D	Strong	Genetic Variation	[66]
GCK	TTDLNGZ	Strong	Posttranslational Modification	[67]
GDF15	TT4MXVG	Strong	Biomarker	[68]
GJA4	TTQO1VY	Strong	Genetic Variation	[69]
GP6	TTTJUVZ	Strong	Biomarker	[70]
HRH2	TTQHJ1K	Strong	Genetic Variation	[71]
HSPD1	TT9HL5R	Strong	Biomarker	[31]
IL6	TTT1V78	Strong	Biomarker	[72]
ITGB3	TTJA1ZO	Strong	Genetic Variation	[73]
LCAT	TTGZ91P	Strong	Biomarker	[74]
LDLR	TTH0DUS	Strong	Biomarker	[75]
LIPG	TTHSZXO	Strong	Genetic Variation	[76]
LPA	TTU9LGY	Strong	Biomarker	[77]
MAZ	TT059DA	Strong	Biomarker	[78]
MSR1	TT2TDH9	Strong	Altered Expression	[79]
NPPB	TTY63XT	Strong	Altered Expression	[80]
NPPC	TTRK0B9	Strong	Altered Expression	[81]
NPR1	TTM9IYA	Strong	Altered Expression	[82]
NPR2	TTNB7IF	Strong	Altered Expression	[82]
NPR3	TTWVLS6	Strong	Altered Expression	[82]
OLR1	TTKSND3	Strong	Biomarker	[83]
PCSK9	TTNIZ2B	Strong	Altered Expression	[84]
PLA2G1B	TT9V5JH	Strong	Genetic Variation	[85]
POR	TTOQ9GZ	Strong	Biomarker	[86]
S100A12	TTQ4ESF	Strong	Biomarker	[87]
SCARB1	TTRE324	Strong	Genetic Variation	[66]
SELPLG	TTS5K8U	Strong	Biomarker	[88]
SLC23A2	TTOP832	Strong	Genetic Variation	[89]
THBD	TTAPV67	Strong	Biomarker	[90]
TNFRSF4	TTL31H0	Strong	Altered Expression	[91]
TP53BP1	TTX4UE9	Strong	Genetic Variation	[66]
VKORC1	TTEUC8H	Strong	Genetic Variation	[92]
VSIR	TT51SK8	Strong	Genetic Variation	[93]
CETP	TTFQAYR	Definitive	Altered Expression	[94]
------------------------------------------------------------------------------------


⏷ Show the Full List of 75 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC11	DTWN7FC	Strong	Biomarker	[95]
------------------------------------------------------------------------------------

This Disease Is Related to 4 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP3A7	DERD86B	Strong	Genetic Variation	[96]
PCYT1A	DEQYXD4	Strong	Genetic Variation	[97]
UGT2A1	DEGKRXT	Strong	Genetic Variation	[98]
UGT2B7	DEB3CV1	Strong	Genetic Variation	[96]
------------------------------------------------------------------------------------

This Disease Is Related to 79 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACSL5	OT3L9XO3	Limited	Biomarker	[99]
ACSL6	OT0TT8P8	Limited	Biomarker	[99]
ARHGDIB	OT9PD6CS	Limited	Biomarker	[31]
CAPZB	OTF1A4N0	Limited	Biomarker	[31]
CHGA	OTXYX5JH	Limited	Biomarker	[100]
CKB	OTUCKOTT	Limited	Biomarker	[101]
CKM	OTME0KO7	Limited	Biomarker	[101]
ENO1	OTB1KWJS	Limited	Biomarker	[31]
LDHB	OT9B1CT3	Limited	Biomarker	[31]
PDIA3	OTHPQ0Q3	Limited	Biomarker	[31]
PSMB1	OTYRFBAH	Limited	Biomarker	[31]
RAB7B	OT60A0E9	Limited	Biomarker	[31]
STARD7	OTDUZ296	Limited	Biomarker	[102]
TPM4	OTN4YLYR	Limited	Biomarker	[31]
ANGPTL2	OTB6JG41	Disputed	Genetic Variation	[103]
ENHO	OT91QASK	Disputed	Altered Expression	[104]
FETUB	OT7V07NI	Disputed	Biomarker	[105]
CST3	OTNZ6AO4	moderate	Altered Expression	[106]
ACADS	OTGFANYQ	Strong	Biomarker	[107]
ADAMTS7	OTVKZ1DV	Strong	Genetic Variation	[108]
ADCY9	OT1IZT5K	Strong	Genetic Variation	[109]
APOM	OTI3FQQC	Strong	Biomarker	[110]
APOO	OTAHHRGZ	Strong	Altered Expression	[111]
ARPC1A	OTAEEXGQ	Strong	Genetic Variation	[96]
BET1	OTGX2557	Strong	Biomarker	[112]
BTD	OTJYTQ69	Strong	Genetic Variation	[66]
CARD16	OT4NUHWB	Strong	Genetic Variation	[113]
CARD18	OTBMLB80	Strong	Genetic Variation	[113]
CELSR2	OTON6JSZ	Strong	Genetic Variation	[66]
CIITA	OTRJNZFO	Strong	Biomarker	[114]
CLEC16A	OTLGV5SV	Strong	Genetic Variation	[115]
CLEC1B	OTO38TRG	Strong	Biomarker	[70]
CRTC3	OTVIGVUW	Strong	Genetic Variation	[116]
CXCL16	OTD49T9R	Strong	Biomarker	[117]
DBP	OTE0W7LN	Strong	Biomarker	[118]
DGCR8	OT62LXE4	Strong	Biomarker	[119]
DHX40	OTOL02QN	Strong	Biomarker	[120]
ECHDC3	OTKU2RMC	Strong	Altered Expression	[121]
ELOVL2	OTDAF6U3	Strong	Biomarker	[122]
FAM114A1	OT0208Y4	Strong	Genetic Variation	[66]
FBLN1	OT5MHHOP	Strong	Biomarker	[123]
FCRL3	OTIFXFWL	Strong	Biomarker	[114]
FGB	OT6RKLI9	Strong	Genetic Variation	[124]
FOXD3	OTXYV6GO	Strong	Biomarker	[125]
FRMD5	OTC73XJK	Strong	Genetic Variation	[66]
FSTL1	OT6KEZUD	Strong	Biomarker	[126]
GABRB1	OT4L2SSB	Strong	Genetic Variation	[66]
GLCCI1	OTU0R1CU	Strong	Genetic Variation	[66]
HPSE2	OTGEPP8V	Strong	Genetic Variation	[127]
IGFBP4	OT2HZRBD	Strong	Biomarker	[128]
KCNE5	OTF4JYGZ	Strong	Genetic Variation	[129]
KIF6	OTDH3MR4	Strong	Genetic Variation	[130]
MB	OTYWYL2D	Strong	Biomarker	[131]
MMRN1	OT7ZNYHT	Strong	Genetic Variation	[132]
MRAS	OTNCVCQW	Strong	Genetic Variation	[133]
MTHFD1L	OTV01EFP	Strong	Genetic Variation	[134]
NDUFC2	OT9M119L	Strong	Biomarker	[135]
NLRC4	OTAIA3NA	Strong	Biomarker	[113]
NRDC	OTWBBCXO	Strong	Biomarker	[136]
PAPPA	OTTTG9PG	Strong	Biomarker	[137]
PEAR1	OT2XLTB2	Strong	Genetic Variation	[138]
PI3	OT47MTC3	Strong	Biomarker	[139]
PLA2G6	OT5FL0WU	Strong	Genetic Variation	[85]
PLXNA2	OTNNBJMQ	Strong	Genetic Variation	[140]
POU2F3	OTIOOJWD	Strong	Genetic Variation	[85]
PPBP	OT1FHGQS	Strong	Biomarker	[141]
PRG2	OT0BCPQG	Strong	Biomarker	[142]
PROZ	OTI3TXBE	Strong	Biomarker	[143]
PTX3	OTPXHRKU	Strong	Altered Expression	[72]
SELENBP1	OT3NZNTR	Strong	Biomarker	[118]
SERPINA5	OTTZXPGD	Strong	Biomarker	[144]
SH2D1A	OTLU49I5	Strong	Biomarker	[46]
SRI	OT4R3EAC	Strong	Biomarker	[145]
SULT4A1	OT7AL3KJ	Strong	Biomarker	[146]
TFG	OT2KJENI	Strong	Biomarker	[147]
TMEM231	OTF4UYIE	Strong	Genetic Variation	[66]
TNNI1	OT4GG8ED	Strong	Altered Expression	[148]
TOMM5	OTKXOH4K	Strong	Genetic Variation	[66]
TREML4	OT2VLMTL	Strong	Altered Expression	[149]
------------------------------------------------------------------------------------


⏷ Show the Full List of 79 DOT(s)

References

1	Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy. Pharmacotherapy. 1990;10(2):115-26.
2	Aspirin FDA Label
3	Atorvastatin FDA Label
4	Ticagrelor-Induced Syncope/Bradyarrhythmia. Cureus. 2021 Jan 23;13(1):e12874.
5	Citalopram FDA Label
6	Clopidogrel FDA Label
7	Eptifibatide FDA Label
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
9	Metoprolol FDA Label
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7562).
11	Ranolazine FDA Label
12	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
13	Ticlopidine FDA Label
14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6586).
15	ClinicalTrials.gov (NCT00914420) Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide Stent Versus Taxus . U.S. National Institutes of Health.
16	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7835).
18	ClinicalTrials.gov (NCT01848106) A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI. U.S. National Institutes of Health.
19	ClinicalTrials.gov (NCT01412034) Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects. U.S. National Institutes of Health.
20	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4048).
21	Clinical pipeline report, company report or official report of Momenta Pharmaceuticals.
22	ClinicalTrials.gov (NCT01554800) Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease. U.S. National Institutes of Health.
23	ClinicalTrials.gov (NCT01245634) A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery. U.S. National Institutes of Health.
24	Clinical pipeline report, company report or official report of Avarx.
25	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012886)
26	ClinicalTrials.gov (NCT01626976) A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects. U.S. National Institutes of Health.
27	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020726)
28	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025293)
29	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
30	ClinicalTrials.gov (NCT00409578) Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome. U.S. National Institutes of Health.
31	Proteomic changes related to "bewildered" circulating platelets in the acute coronary syndrome.Proteomics. 2011 Aug;11(16):3335-48. doi: 10.1002/pmic.201000708. Epub 2011 Jul 14.
32	Expression of circulatory dendritic cells and regulatory T-cells in patients with different subsets of coronary artery disease.J Cardiovasc Pharmacol. 2011 May;57(5):542-9. doi: 10.1097/FJC.0b013e3182124c53.
33	Platelets as a novel source of Gremlin-1: Implications for thromboinflammation.Thromb Haemost. 2017 Jan 26;117(2):311-324. doi: 10.1160/TH16-08-0665. Epub 2016 Dec 8.
34	Antibody phage display assisted identification of junction plakoglobin as a potential biomarker for atherosclerosis.PLoS One. 2012;7(10):e47985. doi: 10.1371/journal.pone.0047985. Epub 2012 Oct 24.
35	Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.Circulation. 1994 Oct;90(4):1631-7. doi: 10.1161/01.cir.90.4.1631.
36	Toll-like receptor-4 is upregulated in plaque debris of patients with acute coronary syndrome more than Toll-like receptor-2.Heart Vessels. 2016 Jan;31(1):1-5. doi: 10.1007/s00380-014-0565-9. Epub 2014 Sep 2.
37	The expression and clinical correlations of 4-1BB on peripheral CD4+ T cell subsets in patients with coronary artery disease. A cross-sectional pilot study.Clin Chim Acta. 2018 Dec;487:341-348. doi: 10.1016/j.cca.2018.10.027. Epub 2018 Oct 22.
38	Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors.Med Chem. 2019;15(8):863-872. doi: 10.2174/1573406415666190208124534.
39	Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.J Am Coll Cardiol. 2013 Nov 19;62(21):1966-1976. doi: 10.1016/j.jacc.2013.06.044. Epub 2013 Jul 31.
40	Common polymorphisms of cyclooxygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery disease.Thromb Haemost. 2008 Nov;100(5):893-8.
41	Association of OX40 and OX40L gene polymorphisms with acute coronary syndrome in a Han Chinese population.DNA Cell Biol. 2011 Aug;30(8):597-602. doi: 10.1089/dna.2010.1201. Epub 2011 Apr 10.
42	Elevated level of ADAMTS4 in plasma and peripheral monocytes from patients with acute coronary syndrome.Clin Res Cardiol. 2010 Dec;99(12):781-6. doi: 10.1007/s00392-010-0183-1. Epub 2010 Jul 13.
43	Association of -Adrenergic Receptor Gene Polymorphisms With Acute Coronary Syndrome and Cardiovascular Risk Factors in an Arab Population.Angiology. 2016 Sep;67(8):762-71. doi: 10.1177/0003319715618039. Epub 2015 Nov 24.
44	Neurovascular control during exercise in acute coronary syndrome patients with Gln27Glu polymorphism of 2-adrenergic receptor.PLoS One. 2017 Feb 24;12(2):e0173061. doi: 10.1371/journal.pone.0173061. eCollection 2017.
45	Interrelationships between ALOX5AP polymorphisms, serum leukotriene B4 level and risk of acute coronary syndrome.PLoS One. 2014 Sep 11;9(9):e106596. doi: 10.1371/journal.pone.0106596. eCollection 2014.
46	Relationship between quantities of tissue prolapse after percutaneous coronary intervention and neointimal hyperplasia at follow-up on serial optical coherence tomography examination.Int J Cardiol. 2017 Aug 15;241:470-477. doi: 10.1016/j.ijcard.2017.01.155. Epub 2017 Feb 14.
47	Association between Gamma-Glutamyl Transferase and Coronary Atherosclerotic Plaque Vulnerability: An Optical Coherence Tomography Study.Biomed Res Int. 2019 Mar 4;2019:9602783. doi: 10.1155/2019/9602783. eCollection 2019.
48	A 6-Month Follow-Up Study of the Relation between Apolipoprotein E Gene Polymorphism and Major Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome.Cardiology. 2018;140(3):187-193. doi: 10.1159/000491597. Epub 2018 Aug 21.
49	The Role of FAK in the Secretion of MMP9 after CD147 Stimulation in Macrophages.Int Heart J. 2018 Mar 30;59(2):394-398. doi: 10.1536/ihj.17-221. Epub 2018 Mar 20.
50	RNA-sequencing reveals that STRN, ZNF484 and WNK1 add to the value of mitochondrial MT-COI and COX10 as markers of unstable coronary artery disease.PLoS One. 2019 Dec 10;14(12):e0225621. doi: 10.1371/journal.pone.0225621. eCollection 2019.
51	Coactivator-associated arginine methyltransferase 1 targeted by miR-15a regulates inflammation in acute coronary syndrome.Atherosclerosis. 2014 Apr;233(2):349-356. doi: 10.1016/j.atherosclerosis.2014.01.039. Epub 2014 Jan 30.
52	Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61.Cardiovasc Diabetol. 2019 Oct 31;18(1):142. doi: 10.1186/s12933-019-0946-6.
53	Associations of rs1883832 and rs4810485 polymorphisms of CD40 gene with myocardial infarction in the Tunisian population.Biomarkers. 2019 Sep;24(6):530-537. doi: 10.1080/1354750X.2019.1602168. Epub 2019 Jun 4.
54	Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome.Med Intensiva. 2017 Nov;41(8):475-482. doi: 10.1016/j.medin.2016.10.008. Epub 2016 Dec 27.
55	Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial.J Cardiol. 2020 May;75(5):500-506. doi: 10.1016/j.jjcc.2019.09.015. Epub 2019 Nov 5.
56	The association of megalin and cubilin genetic variants with serum levels of 25-hydroxvitamin D and the incidence of acute coronary syndrome in Egyptians: A case control study.J Adv Res. 2019 Sep 24;21:49-56. doi: 10.1016/j.jare.2019.09.006. eCollection 2020 Mar.
57	The Association of Fractalkine Receptor (T280M) Polymorphism in the Pathogenesis of Acute Coronary Syndrome in the Egyptian Population.Curr Pharm Biotechnol. 2018;19(11):869-876. doi: 10.2174/1389201019666181031163748.
58	Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):647-652. doi: 10.1161/ATVBAHA.118.311963.
59	Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome.Prostaglandins Other Lipid Mediat. 2018 Sep;138:15-22. doi: 10.1016/j.prostaglandins.2018.07.005. Epub 2018 Aug 7.
60	Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.Blood Adv. 2018 Mar 27;2(6):715-730. doi: 10.1182/bloodadvances.2017013573.
61	Acute coronary syndromes do not promote prolonged in vivo FXII-dependent prothrombotic activity.Thromb Res. 2005;115(1-2):65-72. doi: 10.1016/j.thromres.2004.08.011.
62	Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial.J Am Heart Assoc. 2018 Dec 18;7(24):e009609. doi: 10.1161/JAHA.118.009609.
63	Levels of Alternatively Spliced Tissue Factor in the Plasma of Patients with Pancreatic Cancer May Help Predict Aggressive Tumor Phenotype.Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1206-11. doi: 10.1245/s10434-015-4592-2. Epub 2015 May 12.
64	The decanucleotide polymorphism in the factor VII promoter predicts factor VII plasma levels but not the risk of acute coronary syndromes.J Thromb Thrombolysis. 2000 Aug;10(1):23-8. doi: 10.1023/a:1018790519492.
65	Effects of soluble epoxide hydrolase inhibitor on the expression of fatty acid synthase in peripheral blood mononuclear cell in patients with acute coronary syndrome.Lipids Health Dis. 2013 Jan 10;12:3. doi: 10.1186/1476-511X-12-3.
66	Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.PLoS One. 2017 Jul 28;12(7):e0182115. doi: 10.1371/journal.pone.0182115. eCollection 2017.
67	Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients.J Clin Lab Anal. 2020 Feb;34(2):e23040. doi: 10.1002/jcla.23040. Epub 2019 Oct 11.
68	Growth-differentiation factor-15 predicts adverse cardiac events in patients with acute coronary syndrome: A meta-analysis.Am J Emerg Med. 2019 Jul;37(7):1346-1352. doi: 10.1016/j.ajem.2019.04.035. Epub 2019 Apr 19.
69	Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome.Am Heart J. 2007 Sep;154(3):561-6. doi: 10.1016/j.ahj.2007.04.059.
70	Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with soluble GPVI.Int J Hematol. 2019 Sep;110(3):285-294. doi: 10.1007/s12185-019-02680-4. Epub 2019 Jun 5.
71	Effect of therapeutic interchange on medication reconciliation during hospitalization and upon discharge in a geriatric population.PLoS One. 2017 Oct 19;12(10):e0186075. doi: 10.1371/journal.pone.0186075. eCollection 2017.
72	Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial.Eur Heart J Acute Cardiovasc Care. 2020 Jun;9(4):313-322. doi: 10.1177/2048872619846334. Epub 2019 Apr 24.
73	Platelet glycoprotein IIb HPA-3 polymorphism and acute coronary syndromes.Int J Cardiol. 2008 Jun 23;127(1):46-50. doi: 10.1016/j.ijcard.2007.04.039. Epub 2007 Jun 11.
74	Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome.Arterioscler Thromb Vasc Biol. 2019 May;39(5):915-924. doi: 10.1161/ATVBAHA.118.311987.
75	Prevalence of Achilles tendon xanthoma and familial hypercholesterolemia in patients with coronary artery disease undergoing percutaneous coronary intervention.Heart Vessels. 2019 Oct;34(10):1595-1599. doi: 10.1007/s00380-019-01400-6. Epub 2019 Apr 9.
76	Endothelial lipase-384A/C polymorphism is associated with acute coronary syndrome and lipid status in elderly Uygur patients in Xinjiang.Genet Test Mol Biomarkers. 2014 Nov;18(11):781-4. doi: 10.1089/gtmb.2014.0195. Epub 2014 Oct 7.
77	Prognostic Value of Lipoprotein(a) Levels in Patients Undergoing Coronary Angiography for Premature Acute Coronary Syndromes.Angiology. 2020 Feb;71(2):160-166. doi: 10.1177/0003319719886493. Epub 2019 Nov 13.
78	Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?.Front Immunol. 2017 Nov 21;8:1595. doi: 10.3389/fimmu.2017.01595. eCollection 2017.
79	Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromes.Protein J. 2012 Aug;31(6):511-8. doi: 10.1007/s10930-012-9431-8.
80	Cardiovascular complications and its relationship with functional outcomes in Guillain-Barr syndrome.QJM. 2020 Feb 1;113(2):93-99. doi: 10.1093/qjmed/hcz225.
81	Plasma brain natriuretic peptide levels in coronary heart disease with preserved systolic function.Clin Exp Med. 2004 Sep;4(1):44-9. doi: 10.1007/s10238-004-0037-0.
82	Role of epicardial adipose tissue NPR-C in acute coronary syndrome.Atherosclerosis. 2019 Jul;286:79-87. doi: 10.1016/j.atherosclerosis.2019.05.010. Epub 2019 May 9.
83	Stratification by Multidimensional Approach for Rational Treatment of Asymptomatic Carotid Stenosis (SMART-K Study): Study Protocol.Neurol Med Chir (Tokyo). 2020 Jan 15;60(1):10-16. doi: 10.2176/nmc.st.2019-0188. Epub 2019 Nov 9.
84	The relationship between protein convertase subtilisin kexin type-9 levels and extent of coronary artery disease in patients with non-ST-elevation myocardial infarction.Coron Artery Dis. 2020 Jan;31(1):81-86. doi: 10.1097/MCA.0000000000000774.
85	Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?.Ann Pharmacother. 2005 Jun;39(6):1013-8. doi: 10.1345/aph.1E227. Epub 2005 Apr 19.
86	Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes.Platelets. 2018 Jul;29(5):528-530. doi: 10.1080/09537104.2018.1457782. Epub 2018 Apr 4.
87	The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event.Atherosclerosis. 2019 Aug;287:16-23. doi: 10.1016/j.atherosclerosis.2019.05.020. Epub 2019 May 24.
88	P-Selectin Glycoprotein Ligand-1 (PSGL-1) Expressing CD4 T Cells Contribute Plaque Instability in Acute Coronary Syndrome.Circ J. 2018 Jul 25;82(8):2128-2135. doi: 10.1253/circj.CJ-17-1270. Epub 2018 Jun 30.
89	Variation in the sodium-dependent vitamin C transporter 2 gene is associated with risk of acute coronary syndrome among women.PLoS One. 2013 Aug 21;8(8):e70421. doi: 10.1371/journal.pone.0070421. eCollection 2013.
90	Thrombomodulin can predict the incidence of second events in patients with acute coronary syndrome: Single-center, retrospective cohort study.J Cardiol. 2018 Dec;72(6):494-500. doi: 10.1016/j.jjcc.2018.05.006. Epub 2018 Jun 7.
91	High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome.Circ Res. 2012 Mar 16;110(6):857-69. doi: 10.1161/CIRCRESAHA.111.261933. Epub 2012 Jan 26.
92	Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.Blood Coagul Fibrinolysis. 2015 Jul;26(5):499-504. doi: 10.1097/MBC.0000000000000272.
93	Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.JAMA Cardiol. 2019 Apr 1;4(4):314-320. doi: 10.1001/jamacardio.2019.0179.
94	Association of Serum Cholesterol Ester Transfer Protein Levels with Taq IB Polymorphism in Acute Coronary Syndrome.Lab Med. 2020 Mar 10;51(2):199-210. doi: 10.1093/labmed/lmz043.
95	Myeloid-related protein-8/14 in acute coronary syndrome.Int J Cardiol. 2017 Dec 15;249:25-31. doi: 10.1016/j.ijcard.2017.09.020. Epub 2017 Sep 20.
96	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015 Aug 1;36(29):1901-12.
97	Coronary CT angiography in the emergency department utilizing second and third generation dual source CT.J Cardiovasc Comput Tomogr. 2017 Jul-Aug;11(4):249-257. doi: 10.1016/j.jcct.2017.03.002. Epub 2017 Mar 22.
98	Study of the Association of PEAR1, P2Y12, and UGT2A1 Polymorphisms with Platelet Reactivity in Response to Dual Antiplatelet Therapy in Chinese Patients.Cardiology. 2018;140(1):21-29. doi: 10.1159/000488101. Epub 2018 Apr 10.
99	Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?.Thromb Haemost. 2018 May;118(S 01):S12-S22. doi: 10.1055/s-0038-1636530. Epub 2018 Mar 22.
100	Plasma Catestatin in Patients with Acute Coronary Syndrome.Cardiology. 2017;136(3):164-169. doi: 10.1159/000448987. Epub 2016 Sep 29.
101	The relationship between trace elements and cardiac markers in acute coronary syndromes.J Trace Elem Med Biol. 2005;18(3):235-42. doi: 10.1016/j.jtemb.2004.12.002.
102	Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.Eur Heart J. 2019 Jan 7;40(2):180-186. doi: 10.1093/eurheartj/ehy812.
103	Preliminary study of the relationship between promoter methylation of the ANGPTL2 gene and coronary heart disease.J Clin Lab Anal. 2019 Mar;33(3):e22702. doi: 10.1002/jcla.22702. Epub 2018 Nov 21.
104	Adropin: Connection between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease.Med Princ Pract. 2020;29(1):97. doi: 10.1159/000502039. Epub 2019 Jul 11.
105	Increased serum levels of fetuin B in patients with coronary artery disease.Endocrine. 2017 Oct;58(1):97-105. doi: 10.1007/s12020-017-1387-1. Epub 2017 Aug 19.
106	Association of serum cystatin C levels with acute coronary syndrome in patients of advanced age.J Int Med Res. 2019 May;47(5):1987-1997. doi: 10.1177/0300060519833576. Epub 2019 Mar 14.
107	Difference in clinical presentations and related angiographic findings among early, late, and very late sirolimus-eluting stent failures requiring target lesion revascularization.Int J Cardiol. 2017 Sep 15;243:116-120. doi: 10.1016/j.ijcard.2017.05.052. Epub 2017 May 13.
108	Association of serum ADAMTS7 levels and genetic variant rs1994016 with acute coronary syndrome in a Chinese population: A case control study.Atherosclerosis. 2018 Aug;275:312-318. doi: 10.1016/j.atherosclerosis.2018.06.872. Epub 2018 Jun 21.
109	Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015 Apr;8(2):372-82. doi: 10.1161/CIRCGENETICS.114.000663. Epub 2015 Jan 11.
110	Vehicle-dependent Effects of Sphingosine 1-phosphate on Plasminogen Activator Inhibitor-1 Expression.J Atheroscler Thromb. 2017 Sep 1;24(9):954-969. doi: 10.5551/jat.37663. Epub 2017 Mar 17.
111	Plasma apolipoprotein O level increased in the patients with acute coronary syndrome.J Lipid Res. 2012 Sep;53(9):1952-7. doi: 10.1194/jlr.P023028. Epub 2012 Jun 12.
112	BET 1: IN PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME, DOES WELLENS' SIGN ON THE ELECTROCARDIOGRAPH IDENTIFY CRITICAL LEFT ANTERIOR DESCENDING ARTERY STENOSIS?.Emerg Med J. 2017 Apr;34(4):264-266. doi: 10.1136/emermed-2017-206665.1.
113	NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO).Circ Cardiovasc Genet. 2015 Jun;8(3):498-506. doi: 10.1161/CIRCGENETICS.114.000724. Epub 2015 Mar 6.
114	MHC2TA and FCRL3 genes are not associated with rheumatoid arthritis in Mexican patients.Rheumatol Int. 2016 Feb;36(2):249-54. doi: 10.1007/s00296-015-3358-2. Epub 2015 Sep 8.
115	Association of the C-type lectin-like domain family-16A (CLEC16A) gene polymorphisms with acute coronary syndrome in Mexican patients.Immunol Lett. 2014 Dec;162(2 Pt B):247-51. doi: 10.1016/j.imlet.2014.10.003. Epub 2014 Oct 14.
116	Cyclic adenosine monophosphate-regulated transcriptional co-activator 3 polymorphism in Chinese patients with acute coronary syndrome.Medicine (Baltimore). 2018 Jul;97(27):e11382. doi: 10.1097/MD.0000000000011382.
117	C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes.Arterioscler Thromb Vasc Biol. 2019 Nov;39(11):2402-2410. doi: 10.1161/ATVBAHA.119.312633. Epub 2019 Sep 26.
118	Hypertensive emergencies and urgencies: a single-centre experience in Northern Italy 2008-2015.J Hypertens. 2020 Jan;38(1):52-58. doi: 10.1097/HJH.0000000000002213.
119	Hyperglycemia Determines Increased Specific MicroRNAs Levels in Sera and HDL of Acute Coronary Syndrome Patients and Stimulates MicroRNAs Production in Human Macrophages.PLoS One. 2016 Aug 12;11(8):e0161201. doi: 10.1371/journal.pone.0161201. eCollection 2016.
120	Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease.Minerva Med. 2019 Oct;110(5):410-418. doi: 10.23736/S0026-4806.19.05859-2. Epub 2019 May 6.
121	The relationship of the oleic acid level and ECHDC3 mRNA expression with the extent of coronary lesion.Lipids Health Dis. 2016 Sep 1;15(1):144. doi: 10.1186/s12944-016-0312-6.
122	A case-control study between gene polymorphisms of polyunsaturated fatty acid metabolic rate-limiting enzymes and acute coronary syndrome in Chinese Han population.Biomed Res Int. 2013;2013:928178. doi: 10.1155/2013/928178. Epub 2013 Feb 28.
123	Fibulin? and fibulin? as ruleout tests for non-STelevation myocardial infarction in the emergency setting.Kardiol Pol. 2019 Dec 19;77(12):1170-1175. doi: 10.33963/KP.15041. Epub 2019 Oct 30.
124	Impact of -455G/a polymorphism of the -fibrinogen gene on platelet aggregation in patients with acute coronary syndrome.Clin Appl Thromb Hemost. 2014 Apr;20(3):238-43. doi: 10.1177/1076029613508601. Epub 2013 Nov 6.
125	Prolonged hypothalamic-pituitary-adrenal axis activation after acute coronary syndrome in the GENESIS-PRAXY cohort.Eur J Prev Cardiol. 2018 Jan;25(1):65-72. doi: 10.1177/2047487317734323. Epub 2017 Oct 3.
126	Follistatin-like 1 in Cardiovascular Disease and Inflammation.Mini Rev Med Chem. 2019;19(16):1379-1389. doi: 10.2174/1389557519666190312161551.
127	Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death.Circulation. 2001 Aug 21;104(8):876-80. doi: 10.1161/hc3301.094907.
128	Glycosylated and non-glycosylated NT-IGFBP-4 in circulation of acute coronary syndrome patients.Clin Biochem. 2018 May;55:56-62. doi: 10.1016/j.clinbiochem.2018.03.004. Epub 2018 Mar 8.
129	KCNE5 polymorphism rs697829 is associated with QT interval and survival in acute coronary syndromes patients.J Cardiovasc Electrophysiol. 2012 Mar;23(3):319-24. doi: 10.1111/j.1540-8167.2011.02192.x. Epub 2011 Oct 10.
130	Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.J Am Coll Cardiol. 2008 Jan 29;51(4):449-55. doi: 10.1016/j.jacc.2007.10.017.
131	Trends in Use of Biomarker Protocols for the Evaluation of Possible Myocardial Infarction.J Am Heart Assoc. 2017 Sep 22;6(9):e005852. doi: 10.1161/JAHA.117.005852.
132	Glycoprotein Ia C807T: Polymorphisms and Their Association with Platelet Function in Patients with the Acute Coronary Syndrome.Cardiology. 2015;132(4):213-20. doi: 10.1159/000435906. Epub 2015 Aug 15.
133	MRAS gene marker rs9818870 is not associated with acute coronary syndrome in the Czech population and does not predict mortality in males after acute coronary syndrome.Adv Clin Exp Med. 2017 Nov;26(8):1213-1217. doi: 10.17219/acem/67460.
134	Rs6922269 marker at the MTHFD1L gene predict cardiovascular mortality in males after acute coronary syndrome.Mol Biol Rep. 2015 Aug;42(8):1289-93. doi: 10.1007/s11033-015-3870-1. Epub 2015 Mar 26.
135	The reduction of NDUFC2 expression is associated with mitochondrial impairment in circulating mononuclear cells of patients with acute coronary syndrome.Int J Cardiol. 2019 Jul 1;286:127-133. doi: 10.1016/j.ijcard.2019.02.027. Epub 2019 Feb 14.
136	Increased serum nardilysin is associated with worse long-term outcome of ST-elevation myocardial infarction.Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):7938-7944. doi: 10.26355/eurrev_201811_16421.
137	Pregnancy-Associated Plasma Protein A Induces Inflammatory Cytokine Expression by Activating IGF-I/PI3K/Akt Pathways.Mediators Inflamm. 2019 Sep 10;2019:8436985. doi: 10.1155/2019/8436985. eCollection 2019.
138	Genetic mutations in PEAR1 associated with cardiovascular outcomes in Chinese patients with acute coronary syndrome.Thromb Res. 2018 Mar;163:77-82. doi: 10.1016/j.thromres.2018.01.026. Epub 2018 Feb 2.
139	Expression of tissue transglutaminase and elafin in human coronary artery: implication for plaque instability.Atherosclerosis. 2002 Jan;160(1):31-9. doi: 10.1016/s0021-9150(01)00542-1.
140	Characteristics and significance of healed plaques in patients with acute coronary syndrome and stable angina: an in vivo OCT and IVUS study.EuroIntervention. 2019 Oct 4;15(9):e771-e778. doi: 10.4244/EIJ-D-18-01175.
141	Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation.J Am Coll Cardiol. 2006 Oct 17;48(8):1591-9. doi: 10.1016/j.jacc.2006.06.060. Epub 2006 Sep 27.
142	Pregnancy-associated plasma protein A and proform eosinophilic major basic protein in the detection of different types of coronary artery disease.Physiol Res. 2008;57(1):23-32. doi: 10.33549/physiolres.930986. Epub 2007 Jan 2.
143	[Protein Z: a new regulator of coagulation in arterial vessels?].Ann Pharm Fr. 2004 Sep;62(5):316-22. doi: 10.1016/s0003-4509(04)94320-9.
144	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.Circulation. 2020 Mar 3;141(9):781-783. doi: 10.1161/CIRCULATIONAHA.119.044584. Epub 2019 Nov 11.
145	Application of Risks Scores in Acute Coronary Syndromes. How Does ProACS Hold Up Against Other Risks Scores?.Arq Bras Cardiol. 2019 Jun 27;113(1):20-30. doi: 10.5935/abc.20190109.
146	The antithrombotic activity of the active fractions from the fruits of Celastrus orbiculatus Thunb through the anti-coagulation, anti-platelet activation and anti-fibrinolysis pathways.J Ethnopharmacol. 2019 Sep 15;241:111974. doi: 10.1016/j.jep.2019.111974. Epub 2019 May 24.
147	Transforming Growth Factor Beta (TFG-) Concentration Isoforms are Diminished in Acute Coronary Syndrome.Cell Biochem Biophys. 2018 Sep;76(3):433-439. doi: 10.1007/s12013-018-0849-2. Epub 2018 Jul 12.
148	Myocardial injury in critically ill patients: relation to increased cardiac troponin I and hospital mortality.Chest. 2005 Oct;128(4):2758-64. doi: 10.1378/chest.128.4.2758.
149	TREML4 mRNA Expression and Polymorphisms in Blood Leukocytes are Associated with Atherosclerotic Lesion Extension in Coronary Artery Disease.Sci Rep. 2019 May 10;9(1):7229. doi: 10.1038/s41598-019-43745-y.